Aeon Biopharma Q3 2026 Results: Turns Profitable, Net Income $2.46M
AEON Biopharma reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a $2.1 million loss in the prior year period. The company significantly strengthened its balance sheet through public offerings and PIPE financing, increasing cash and cash equivalents to $11.4 million and reducing total liabilities from $60.6 million to $11.7 million.
- Key figure
- Net income $2.46M